Proteostasis Therapeutics (Proteostasis Therapeutics) Price-to-Tangible-Book : 1.56 (As of May. 11, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Proteostasis Therapeutics Price-to-Tangible-Book?

As of today (2024-05-11), Proteostasis Therapeutics's share price is $1.11. Proteostasis Therapeutics's Tangible Book per Share of Sep. 2020 for the quarter that ended in Sep. 2020 was $0.71. Hence, Proteostasis Therapeutics's Price to Tangible Book Ratio of today is 1.56.

The historical rank and industry rank for Proteostasis Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

PTI's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.7
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Proteostasis Therapeutics's share price is $1.11. Proteostasis Therapeutics's Book Value per Sharefor the quarter that ended in Sep. 2020 was $0.71. Hence, Proteostasis Therapeutics's P/B Ratio of today is 1.56.

Proteostasis Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Proteostasis Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteostasis Therapeutics Price-to-Tangible-Book Chart

Proteostasis Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Price-to-Tangible-Book

Get a 7-Day Free Trial

75.26

58.33

28.80

38.10

Proteostasis Therapeutics Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Price-to-Tangible-Book	Get a 7-Day Free Trial															12.33	38.10	22.37	31.79	30.94

Competitive Comparison of Proteostasis Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Proteostasis Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Proteostasis Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Proteostasis Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Proteostasis Therapeutics's Price-to-Tangible-Book falls into.

Proteostasis Therapeutics Price-to-Tangible-Book Calculation

Proteostasis Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Sep. 2020 )
	=	1.11	/	0.711
	=	1.56

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Proteostasis Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Proteostasis Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Proteostasis Therapeutics (Proteostasis Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteostasis Therapeutics Inc (NAS:PTI) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Guest Street, Suite 500, 5th Floor, Boston, MA, USA, 02135

Website

http://www.proteostasis.com

Proteostasis Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis (CF) through theratyping, or the process of matching modulators to individual response to treatment regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutations. All of the company's revenue is collaboration or license revenue earned from activities in the United States.

Executives

Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Badrul A. Chowdhury	director	PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Jeffrey W. Kelly	director	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Emmanuel Dulac	director	PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
David Arkowitz	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael Alfieri	officer: Interim Head of Finance	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Greffrey S. Gilmartin	officer: Chief Medical Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Meenu Chhabra	director, officer: President and CEO	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Sheila Wilson	officer: Chief Operating Officer	C/O PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
Benito Munoz	officer: Chief Scientific Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Eric D Larson	officer: See Remarks	C/O NORTHERN POWER SYSTEMS CORP., 29 PITMAN ROAD, BARRE VT 05641
Marija Zecevic	officer: Chief Commercial Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
New Enterprise Associates 12, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202